Omnicell (OMCL) Misses Q3 EPS by 1c

Omnicell (NASDAQ: OMCL) reported Q3 EPS of $0.40, $0.01 worse than the analyst estimate of $0.41. Revenue for the quarter came in at $176.7 million versus the consensus estimate of $179.75 million.

"Omnicell completed another strong quarter marked by record revenues and market share gains," said Randall Lipps, Omnicell President, CEO and Chairman. "Omnicell's continued growth is the result of successfully broadening our product portfolio, expanding the markets we participate in, and partnering with our customers to address medication management across the full continuum of patient care. The Company is well positioned to take advantage of the great opportunities ahead," Mr. Lipps added.

For earnings history and earnings-related data on Omnicell (OMCL) click here.

You May Also Be Interested In

• KB Home (KBH) Tops Q3 EPS by 16c
• Willdan to buy Mantis Innovation for $285M in cash
• Sun Communities completes $1.03B sale of Park Holidays to Aermont